How Alcohol Dehydrogenase and Aldehyde Dehydrogenase Metabolize Ethanol to Acetate, and Why Genetic Variants Cause Flushing

The human body metabolizes alcohol through a strict two-step process: the enzyme alcohol dehydrogenase (ADH) first converts ethanol into a highly toxic intermediate called acetaldehyde, which a second enzyme, aldehyde dehydrogenase (ALDH), then rapidly neutralizes into harmless acetate. When a person experiences the alcohol flush reaction—characterized by facial redness, rapid heart rate, and nausea—it is because a genetic variant has disabled that second enzyme, causing the toxic acetaldehyde to accumulate in the bloodstream rather than being cleared.[1][4]

The detoxification assembly line begins primarily in the liver. When ethanol enters the digestive tract and bloodstream, it encounters the ADH family of enzymes. These enzymes strip hydrogen atoms from the ethanol molecule, oxidizing it. This initial conversion is a necessary step to remove alcohol from the blood, but it creates a dangerous byproduct. Acetaldehyde is significantly more toxic than ethanol itself; it is a known carcinogen that binds to proteins, damages DNA, and triggers the release of histamine.[4][6]

Because acetaldehyde is so destructive, the body cannot allow it to linger. Under normal metabolic conditions, the mitochondrial enzyme ALDH2 immediately catches the acetaldehyde and oxidizes it a second time. This reaction transforms the toxic aldehyde into acetic acid, or acetate. Acetate is a benign compound that safely leaves the liver, circulates to peripheral tissues, and is eventually broken down into carbon dioxide and water. When both enzymes work in tandem, the toxic intermediate exists only briefly.[2][4]

For an estimated 560 million people globally—roughly 8 percent of the world's population, including 20 to 30 percent of people of East Asian descent—this assembly line is broken. A single base change in the ALDH2 gene produces the ALDH2*2 allele. This mutation alters the structure of the ALDH2 enzyme, rendering it essentially inactive. When individuals with this variant consume alcohol, their ADH enzymes successfully convert the ethanol into acetaldehyde, but the defective ALDH2 enzymes cannot clear it.[1][3][6]

The result is a severe metabolic bottleneck. Blood acetaldehyde levels spike dramatically, flooding the systemic circulation. The body responds to this circulating toxin with acute vasodilation, causing the skin of the face and body to flush deep red. The accumulation also triggers tachycardia, and what clinical literature describes as "nausea, headache and general physical discomfort." This response is not an immune allergy to alcohol, but a direct chemical poisoning by its primary metabolite.[6][7]

The severity of this bottleneck is often compounded by variants in the first step of the pathway. Many individuals who carry the ALDH2*2 mutation also carry a variant of the ADH gene, such as ADH1B*2. This allele encodes a superactive version of the alcohol dehydrogenase enzyme. A superactive ADH enzyme converts ethanol into acetaldehyde much faster than the standard variant. When paired with an inactive ALDH2 enzyme, the body produces the toxin rapidly but cannot clear it, maximizing the peak concentration of acetaldehyde in the blood.[1][7]

The consequences of this metabolic failure extend far beyond temporary discomfort. Acetaldehyde is a mutagen that forms adducts—chemical bonds—with DNA, leading to chromosomal damage. Individuals who are heterozygous for the ALDH2*2 variant, carrying one normal allele and one defective allele, experience a less severe flush, which sometimes allows them to develop a behavioral tolerance and drink moderately. However, clinical data published in 2009 shows that these individuals face a drastically elevated risk of esophageal squamous cell carcinoma. Studies indicate that low-activity ALDH2 heterozygotes who drink have an esophageal cancer risk 3.7 to 18.1 times higher than those with fully active enzymes.[6][7]

Because the symptoms are so distinct, medical professionals do not necessarily need genetic sequencing to identify the risk. As researchers noted in a 2009 PLOS Medicine analysis, "clinicians can determine ALDH2 deficiency simply by asking about previous episodes of alcohol-induced flushing." Despite this easily identifiable biomarker, public awareness remains low, and the flush is frequently dismissed as a cosmetic inconvenience rather than a warning sign of carcinogen exposure.[7][8]

The prevalence of the ALDH2*2 variant in East Asian populations is not a random genetic drift, but a result of strong natural selection over the last 2,000 to 3,000 years. Evolutionary biologists note that the rise of this allele corresponds closely with the spread of rice domestication and the advent of fermented alcoholic beverages. The intensely aversive symptoms of the flush reaction likely served as a protective behavioral deterrent, discouraging heavy alcohol consumption and thereby protecting carriers from alcoholism and alcohol-related liver disease.[1][6]

Understanding this precise mechanism has opened new avenues for medical intervention. Researchers are currently investigating small-molecule drugs, such as Alda-1, which act as molecular chaperones. These compounds bind to the defective ALDH2*2 enzyme and restore its structural integrity, partially reactivating its ability to metabolize acetaldehyde. While not intended to facilitate drinking, such therapies could eventually protect individuals with the variant from the ambient aldehydes produced by cellular stress, offering a targeted defense against genetic vulnerability.[5][8]